Pheochromocytoma and Paragangliomas: Current Management Strategies

Area of Science:

• Endocrinology
• Oncology
• Surgical Pathology

Background:

• Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors originating from chromaffin cells.
• These tumors present complex clinical challenges, including potential for malignancy and varied hormonal activity.
• Current management relies on a multidisciplinary approach due to the heterogeneity of PPGLs.

Purpose of the Study:

• To review recent advancements in the diagnosis and management of pheochromocytomas and paragangliomas.
• To highlight progress in biochemical testing, imaging modalities, genetic counseling, and surgical techniques.
• To discuss emerging therapeutic strategies for metastatic disease and challenges in global healthcare access.

Main Methods:

• Comprehensive literature review of recent studies on PPGL diagnosis and treatment.
• Analysis of current guidelines and emerging research in biochemical assays, imaging technologies (e.g., MIBG, DOTATATE PET), and genetic testing.
• Evaluation of surgical approaches, including minimally invasive and open techniques.
• Review of novel systemic therapies, including targeted agents and radioligand therapy.

Main Results:

• Significant improvements in diagnostic accuracy achieved through enhanced biochemical testing and advanced imaging.
• Minimally invasive surgery is increasingly preferred, offering better patient outcomes, though open surgery remains crucial for complex cases.
• Emerging treatments like targeted therapies and radioligand therapy show promise for metastatic PPGLs.
• Global disparities in access to advanced diagnostic and therapeutic options persist.

Conclusions:

• Integrated diagnostic and therapeutic strategies have markedly improved outcomes for patients with pheochromocytomas and paragangliomas.
• Multidisciplinary care and continued research are essential to address the complexities and optimize management of these rare tumors.
• Addressing global inequities in healthcare access is critical for equitable patient care worldwide.